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demonstrated that IFX-treated patients could gain economic
beneﬁt by retaining employability over time.
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ORALVS INJECTABLETREATMENTS: PATIENT PREFERENCE
IN BRAZILIAN PATIENTS
Boscatti FHG
Produtos Roche Químicos e Farmacêuticos S.A, São Paulo, SP, Brazil
OBJECTIVE: To assess the preference of Brazilians for drugs
with different dosing and methods of application to treat chronic
diseases, such as osteoporosis. The assessed product types were:
once-monthly oral, injection once every three months, and
once-yearly injection. METHODS: Quantitative study per-
formed through personal and individual interviews. A represen-
tative sample of the study population (N = 392 subjects) was
used. Subjects over 45 years old were interviewed. A 14-item
structured questionnaire was used. A card with the drug charac-
teristics (dosing, cares of administration, side effects and annual
treatment cost) was shown to the interviewed subjects.
RESULTS: Fourty-four percent of the interviewed subjects were
male and 56% were female. Sixty percent of the interviewed
subjects were between 45 and 59 years old, and the other 40%
were 60 years old or more. Fourteen percent of the interviewed
subjects belonged to the Brazilian socioeconomic classiﬁcation
“A”, followed by 39% in the classiﬁcation “B”, and 47% in the
classiﬁcation “C”. Twenty-eight percent had higher education,
followed by 29% with secondary education, and 42% with
primary education. Ninety-three percent of the interviewed sub-
jects do not usually take injection drugs. For treatment of chronic
diseases, 72% of the patients prefer oral drugs, 16% prefer
injection drugs diluted in serum, 9% prefer injection drugs, and
3% did not inform their preference. These percentages remained
the same when dosing, side effects and prices were disclosed.
83% of the patients who chose oral drug did it so by convenience
of the dosing, 21% of them also think that oral drugs have fewer
side effects than injection drugs. Generically comparing (not
considering the card with product proﬁles) oral and injection
drugs, 78% of the population prefer oral treatments. CONCLU-
SION: If patients are given the chance to choose between oral or
injection drugs to treat chronic diseases, 78% prefer oral drugs
instead of injection ones.
PMS41
UTILIZATION AND COSTS OF DRUGS AND OFFICE SERVICES
AMONG RECIPIENTS OF MEDICAIDWITH RHEUMATOID
ARTHRITISWITHVERSUSWITHOUT COMORBID
DEPRESSION
Khanna R1, Smith MJ1, Kamal KM2
1West Virginia University, Morgantown,WV, USA, 2Duquesne
University, Pittsburgh, PA, USA
OBJECTIVE: To determine the differences in the patterns and
costs of health care utilization between recipients with Rheuma-
toid Arthritis (RA) with versus without comorbid depression
enrolled in a state Medicaid program. METHODS: A retrospec-
tive cross-sectional analysis of a de-identiﬁed state Medicaid
fee-for-service administrative claims dataset was conducted. The
target population included recipients between 15–64 years old
who were continuously eligible for beneﬁts between January 1,
2002 and December 31, 2003. Recipients with at least one
medical services claim with a primary diagnosis of RA in 2002
were selected. The sample was then dichotomized between those
with versus without a medical claim with a primary diagnosis of
depression during 2002. Data from calendar year 2003 was used
to compare the patterns of RA-related ofﬁce services and pre-
scription medication utilization and related costs between the
two groups. RESULTS: There were 763 recipients identiﬁed with
RA, of whom 244 (31.9%) had comorbid depression. A signiﬁ-
cantly (p < 0.05) higher proportion of recipients 21–44 years of
age (41.9%), females (34.4%), and whites (32.0%) with RA had
comorbid depression. Negative binomial regression controlling
for demographic variables and comorbidities showed the fre-
quency of ofﬁce visit utilization was signiﬁcantly (p < 0.05) lower
for recipients with comorbid depression than those without
depression. A signiﬁcantly (p < 0.05) higher proportion of recipi-
ents without depression than with depression had a claim for a
DMARD (49.4% versus 31.9%) and a biologic agent (17.0%
versus 10.0%). The average annual amount paid by Medicaid
per recipient for the use of ofﬁce services and prescription medi-
cations was signiﬁcantly (p < 0.05) higher for recipients without
depression ($2914) than with depression ($2049). CONCLU-
SION: Roughly one-third of the recipients with RA had comor-
bid depression. The use of primary care ofﬁce services and
prescription medications that can slow the progression of RA
was lower among recipients with depression than without
depression.
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USAGE OF ACETAMINOPHEN AND NSAIDS ACCORDINGTO
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OBJECTIVE: Acetaminophen (paracetamol) and non-steroidal
anti-inﬂammatory drugs (NSAIDs) are common prescription
and nonprescription medications for osteoarthritis (OA). British
Columbia (BC) PharmaNet data contains one record for every
prescription. The National Population Heath Survey (NPHS)
includes prescription and nonprescription medications, but the
BC sample is small. Our objective is to explore the utility of large
prescription-only databases in studying drugs with nonprescrip-
tion forms. We compare acetaminophen and NSAIDs according
to OA and disease duration (OAD), and compare results from
NPHS versus PharmaNet. METHODS: Medications in the 2002/
2003 NPHS (Canada = 11717, BC = 1101) refer to the two days
before the interview. Statistics Canada classiﬁed responses by
ATC. OA was self-reported. In Medical Services Plan (MSP) data,
ICD-9 codes determined OA. PharmaNet (n = 100,000) was
linked to MSP, and weighted according to the 2003 BC popula-
tion. Medication use from PharmaNet/NPHS was compared
by age, sex and OAD. RESULTS: PharmaNet: acetaminophen
ranged from 0.04% in ages 0–49 without OA to 6.7% in 50–59
with OAD > 6 years. OAD increased use. NSAID ranged from
0.43% in 0–49 without OA to 10.7% in 70+ with OAD > 6
years. OAD and older age increased use. NPHS: acetaminophen
ranged from 5.1% to 15.8%. OA disease increased use. NSAID
ranged from 8.9% in 0–49 without OA to 32.6% in 70+ with
OAD > 6 years. OAD and older age increased use. The ratio of
acetaminophen in NPHS/PharmaNet ranged from 1.25 (50–59
with OAD > 6 years) to 175.7 (0–49 without OA). The ratio of
NSAID ranged from 3.04 to 20.6. CONCLUSION: In
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self-reported and prescription-only data, acetaminophen was
increased by OA, and unrelated to sex and age after controlling
for OAD. In both datasets, NSAIDs were increased by OAD and
older age, and unrelated to sex. Medication use is higher in
self-reported versus prescription-only data. However, effects are
similar, thus large prescription databases may be advantageous
even for medications with nonprescription forms.
PMS43
CHARACTERISTICS OF PHARMACEUTICS HAVING NO
ALTERNATIVES
Yim EY, Kim DW, Chang JH, Choi DW, Lim SH, Park SE,Yi SY
Health Insurance Review & Assessment Service, Seoul, Seoul, South
Korea
OBJECTIVE: Drugs used in severe status failed in previous treat-
ment are necessary for small target patients even though they are
expensive to cover. However, it’s difﬁcult to assess whether they
should be listed on reimbursement, because most have little
evidence including clinical trial and economic evaluation. There-
fore we analyzed previous submissions to ﬁnd out characteristics
of those drugs. METHODS: We investigated characteristics of 13
submissions of no alternative drugs for reimbursement decision
from 2003 to 2007 in Korea and those drugs’ reimbursement
decisions in other countries. RESULTS: Three drugs (23%) had
high level evidence based on SR and RCT, and 11 drugs were
recommended in clinical guidelines. Eight economic evaluations
(62%) were submitted. Mean additional survival duration was
5.35 month (range 0.8 to 11.1) when life year gained is presented
as outcome value (N = 7, 54%). Two of them compared with
best supportive care or placebo showed ICER was 1.10 GDP/
LYG (0.57 to 1.64) and the others compared with standard
therapy showed lower value of ICER (0.86 GDP/LYG, -0.09 to
2.07). Average net amount of budget impact was 9 million USD
(431 thousand to 44 million USD). Drugs compared with BSC
were almost decided not to be reimbursed except for one drug
having longer additional survival, less ICER and lower budget
impact. On the contrary, those compared with standard therapy
were reimbursed except for one drug having higher ICER(2.07
GDP/LYG) and budget impact. Some drug having low efﬁciency
but low budget impact was listed in Korea. Decisions for reim-
bursement about those drugs were not consistent among
countries (Austrailia, UK, Canada and Korea). CONCLUSION:
Additional life year gained, efﬁciency and budget impact seemed
to affect reimbursement decision in Korea. Further investigation
is required for setting of criteria in reimbursement evaluation of
no alternative drugs, especially having good cost-effectiveness
and high budget impact or the opposite.
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PRESCRIPTIONTREATMENT PATTERNS IN PATIENTSWITH
CHRONIC OSTEOARTHRITIS PAIN
Ng DB1, Mackowiak J2, Slaton T2, Mody S1, Benson C1
1Ortho-McNeil Janssen Scientiﬁc Affairs, LLC, Raritan, NJ, USA,
2Center for Outcomes Research, Chapel Hill, NC, USA
OBJECTIVE: Describe current treatment patterns in patients
(pts) with chronic osteoarthritis (OA) pain, with emphasis on
their opioid therapy. METHODS: Using a large 2006 commer-
cial claims database, continuously enrolled adult OA pts (ICD-9
CM code = 715.XX, 18 years old) with chronic non-
malignant pain were identiﬁed. Those with at least 120 days
supply (ds) of pain medication in 2006 were classiﬁed as having
“chronic pain.” Pts were grouped based on their use of con-
trolled long acting opioids (LAO), controlled short acting
opioids (SAO), and all other non-controlled analgesics. Pt
demographics, comorbidities, and drug utilization were exam-
ined. RESULTS: Of the over 8 million pts in the claims data-
base, 33,221 pts (mean age 54.4; 64.5% female) had “chronic
OA pain.” The most common comorbidities were hypertension
(55.9%), hypercholesterolemia (51.2%), diabetes (19.7%), and
GERD (17.5%). The most common pain-related medications
used were NSAIDs (71.4%), controlled (CII-CIII) opioids
(71.0%), antidepressants (42.5%), anti-ulcer drugs (39.7%),
and musculoskeletal therapy agents (30.0%). Nearly half of pts
(48.1%) had claims for 30 ds of a controlled opioid for pain,
40.3% with 60 ds, and 35.8% with 90 ds of controlled
opioids for pain in 2006. Eleven percent (11%) were prescribed
an LAO (CII-CIII), with 7.7% (2,559/33,221) used a SAO as
monotherapy for pain with least a 120 ds in 2006. Stated dif-
ferently, 12.8% (2,559/19,946) of SAO users and 34.3%
(1,253/3,653) of LAO users did not have a claim for a non-
controlled analgesic utilizing only opioids for prescription pain
control. CONCLUSION: Almost half (48.1%) of chronic OA
pain pts were treated with at least 30 days of controlled opioids
annually with almost one in ten using SAOs as monotherapy for
long term management of their OA pain. Further analyses are
needed to better understand the appropriate and inappropriate
use of opioids in OA patients.
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ATWO-YEAR LONGITUDINAL STUDY OF SWITCHING
PATTERNS AMONG ANTI-TUMOR NECROSIS FACTORS IN
THETREATMENT OF RHEUMATOID ARTHRITIS
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LLC, Philadelphia, PA, USA
OBJECTIVE: To evaluate long-term switching patterns
among anti-TNFs in patients with rheumatoid arthritis (RA).
METHODS: A retrospective study utilizing the PharMetrics
managed-care claims database was conducted. RA patients’ ﬁrst
anti-TNF encounter between January 1, 2000 and December 1,
2006 was identiﬁed. Patients were required to have 30
months of continuous plan eligibility; 6 months prior to and 24
months following their index date, as patients were
followed-up for 24 months after the index biologic date. Rates
of switching and days before switching were compared among
three cohorts based on their index biologic agent (inﬂiximab,
etanercept and adalimumab) plus methotrexate (MTX).
Univariate and multivariate statistical analyses were conducted
to determine if differences existed among the three cohorts.
RESULTS: Of 2155 patients analyzed, 605 (28.1%) received
inﬂiximab therapy, 1121 (52.0%) received etanercept therapy,
and 429 (19.9%) received adalimumab therapy; 75% were
female and the mean age was 49.5 years. Age, gender, Charlson
Comorbidity Index and disease staging were similar among the
three cohorts. During the 24 months follow-up, 376 patients
(17.4%) switched to another anti-TNF: 88 patients (14.5%) in
the inﬂiximab cohort switched compared to 203 (18.1%) in
etanercept group and 85 (19.8%) in the adalimumab group
(p = 0.0728). The mean time to switch for all patients was
342.1 days. The inﬂiximab group had an average time of 395.4
days, compared to 329.7 days in the etanercept group, and
321.0 days in the adalimumab group (P = 0.0173). After con-
trolling for demographic variables and disease severity, differ-
ences among the three cohorts were statistically signiﬁcant
(p < 0.05). CONCLUSION: Switching among therapies is an
important measure of the effectiveness of RA treatment. This
study found that, in a two-year follow-up period, inﬂiximab
plus MTX is associated with a lower switching rate and longer
time before switching, as compared to the other anti-TNFs.
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